The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved tumor treating fields for use as part of combination treatment for certain patients with ...

Lua, the mobile first communications platform for any workforce, has today launched a brand new feature of the product called Insights. Insights is a metrics platform that will allow clients to see in ...

A Des Moines microbrewery is a finalist for the best brewpubs across the U.S., and Iowans have a chance to vote it into the top 10. Lua Brewing was nominated for USA TODAY 10Best's Readers' Choice ...

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) Optune Lua is now approved for use concurrently with ...